A sudden, sustained improvement in glucose markers without corresponding changes in diet or exercise habits is one of the clearest laboratory signatures of GLP-1 therapy
The interest in Mounjaro vs Zepbound stems from their shared composition, but different FDA approvals
[3] [51] [272] The class includes amphetamine itself, stimulants like methamphetamine, serotonergic empathogens like MDMA, and decongestants like ephedrine, among other subgroups
We are not sure what causes this variance as they are both the same in terms of action and strength
These include unexplained fatigue or energy changes, significant mood alterations, palpitations or irregular heartbeat, increased sensitivity to heat or cold, changes in bowel habits beyond expected medication side effects, unexplained hair loss, or skin changes
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 By raising insulin production and reducing glucagon secretion, the hormone glucagon-like peptide-1 (GLP-1) regulates blood sugar levels before and after meals
